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Altruism, Scepticism, and collective
decision-making in foreign-born U.S.
residents in a tuberculosis vaccine trial
Sienna R. Craig1* , Timothy Lahey2, Apoorva Dixit3 and C. Fordham von Reyn2
Abstract
Background: The current vaccine against tuberculosis, BCG, is effective when given in most TB-endemic countries
at birth but has diminished efficacy against pulmonary TB after 15–20 years. As a result, new booster vaccines for
adolescents and adults are being developed to realize the World Health Organization target of global elimination of
TB by 2035. Multiple TB candidates thus are in active clinical development.
Methods: One of these, DAR-901, is advancing in human clinical trials. These clinical trials are conducted in BCG
immunized adults with and without HIV infection in order to assess safety and efficacy among the people most in
need of a new vaccine. A Phase I dose escalation trial of DAR-901 in BCG-immunized adults with or without HIV
infection was conducted between 2014 and 2016. This offered an unusual opportunity to qualitatively examine why
foreign-born adults living in the United States – a poorly studied population – decide to participate, or not, in
clinical trials.
Results: We conducted a qualitative study of individuals who were recruited to participate in this Phase I vaccine
trial, interviewing those who agreed and declined to participate. We found diverse motivations for participation or
refusal; varied understandings of tuberculosis and vaccines; and complex views about how ‘informed consent’ can
be at odds with cultural understandings of power, authority, and medical decision-making. These dynamics
included: knowledge (direct or indirect) of tuberculosis, a desire to be altruistic and simultaneous hopes for
personal gain as well as concerns over what remuneration for participation could mean, the importance of personal
relationships with care providers in shaping volunteerism, concerns over privacy, and evidence of how culture and
history shape medical decision-making.
Conclusions: This US-based trial, aimed at addressing a crucible global health issue, raises productive questions
about the interface between altruism and scepticism regarding clinical research participation.
Trial registration: NCT02063555.
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Background
The World Health Organization has targeted elimination
of tuberculosis (TB) in the world by 2035 [1], a goal felt
unreachable without the introduction of a new and more
effective TB vaccine [2]. The current global vaccine
against TB, known as BCG, is given at birth in most
TB-endemic countries. BCG lowers the incidence of
disseminated TB in children, and likely provides
limited protection from TB later in life, but does not
provide sufficient lifelong protection from TB [3].
Modelling studies indicate that global TB elimination
by 2035 can only be achieved with the development
of a new booster vaccine [4].
More than a dozen TB vaccine candidates are now in
active clinical development [5, 6].1 DAR-901 is the leading
TB vaccine candidate aimed at boosting the protective
efficacy of BCG [7]. A Phase I dose escalation trial recently
found that DAR-901 was safe, tolerable and immunogenic
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[8]. This study was conducted among HIV-negative and
HIV-infected adults in the United States who received
BCG at birth in countries where TB is endemic.
A Phase 1 vaccine study among foreign-born adults in
the United States presents an unusual research oppor-
tunity. While the motivations for American citizens to
participate in US-based clinical trials are well researched
[9–11], as are the motivations for local populations to
participate in global clinical trials [12–16], there is a
relative dearth of literature that addresses study popula-
tions with unique cross-cultural understanding of both
their home country and the US, as sites of clinical
research and medical intervention. Research trials struc-
tured around the recruitment of foreign-born subjects
are uncommon in the United States [17–19]. As a result,
the motivations for foreign-born individuals to partici-
pate in clinical trials – or their decisions not to partici-
pate in such research – are poorly understood. The US-
based DAR-901 trial presented an opportunity to learn
more about volunteerism in a foreign-born population.
Instead of testing a drug or intervention on a ‘treat-
ment naïve’ population which might not expect benefit
from research outcomes [20], the DAR 901-trial was
conducted in the US on individuals who reflected a glo-
bal ‘target population’ of new TB vaccine development:
those at risk of TB mortality and morbidity, including
people living with HIV. For the HIV-infected subset of
potential subjects, the trial was also conducted in a
context of significant pre-existing trust between them
and physician-scientists.2 And yet, early trial recruitment
efforts remained difficult, with the rationales for eligible
participants’ agreement or refusal to participate initially
opaque to study staff.
To assess foreign-born individuals’ motivations to par-
ticipate in a clinical trial, or not, we conducted a qualita-
tive study of those who were both enrolled in and
approached for recruitment into in the Phase I DAR-901
trial. In interviews with 18 enrolled and declined individ-
uals, we found diverse motivations for participation or
refusal; varied understandings of tuberculosis and vac-
cines; and complex views about how informed consent
can be at odds with cultural understandings of power,
authority, and medical decision-making. This US-
based trial provided an unusual opportunity to ad-
dress an issue that is crucial to the success of global
health interventions: how altruism and scepticism
influence medical decision-making regarding clinical
research participation.
Motivations for participation in medical trials include
altruism, the desire to contribute to science, and expect-
ation of personal benefit [12, 20–24]. The predominant
motivator can change from early to late stage trials;
altruism can be supplanted in later-phase trials by
subject expectation of benefit ([25, 26]: p. 112–128).
Subjects may see study participation as solidifying the
therapeutic bond between them and a clinician [27–29].
In US trials, the patient-physician relationship is a
commonly cited motivating factor for participation, but
is rarely acknowledged in the context of global trials
[12, 30]. Ironically, volunteerism can compete with finan-
cial incentives as motivations to participate in clinical tri-
als [31, 32]. This presents an ethically fraught dynamic,
since financial incentives can become coercive [33–35].
The possibility that subjects can be coerced by financial
incentives for study participation varies by age. Vere ([36]:
p. 142) argues that risk acceptance among young subjects
(i.e. college students) is high, and they can ‘deny that pay-
ment is for risk [and] assert that it is for inconvenience’ to
justify participating [37, 38]. This was relevant to our
study in that it was being conducted in a college town,
where many potentially eligible foreign-born, BCG-
vaccinated individuals would be undergraduate or gradu-
ate students.
Motivations not to participate in clinical trials are just
as complicated [39]. Subject willingness to participate
can be dampened by the legacy of unethical clinical
research, from the Tuskegee syphilis experiments to
more-recent controversies like the Development of
AntiRetroviral Therapy (DART) trials in several African
countries [40, 41]. Mistrust of clinical research too can
be amplified by legacies of colonial medicine ([42]:
p. 146–174). As research is conducted increasingly by
private, for-profit and even corporate entities [20], sub-
jects may feel potential community benefit from study
participation has shifted to corporate benefit which is less
motivating [43].
Commonly cited reasons for not volunteering for clin-
ical studies include ‘lifestyle’ conflicts, which may include
cultural or religious sensibilities that advise against
subjecting the body to experimentation or invasive pro-
cedures as well as logistical conflicts with school or work
schedules, etc. [21]. Family members, too, may express
concern about their loved ones being ‘experimented on’
or similar perceptions of possible harm that outweigh
the potential benefits [31, 44].
The complex mixture of motivations to participate, or
not, in clinical research comes to a point in the informed
consent process [9, 45–47]. Even the simple-seeming
decision to give informed consent to participate in a
clinical trial assumes a circumscribed or individualistic
understanding of informed consent. This may be com-
plicated by cultural understandings of power, authority,
and decision-making as well as the scientific vocabular-
ies, standards, and cultural assumptions behind clinical
studies [48–51]. Nurses can play critical roles in recruit-
ment [27, 52]. For instance, subjects are more likely to
understand the premise, process, risks, and benefits of a
clinical trial and to ask questions (and therefore exercise
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more truly ‘informed’ consent) if a nurse, either with a
physician or instead of a physician, works with the re-
search team to explain this concept [17, 25]. This insight
is relevant to the DAR-901 trial. As we describe below,
study staff played a crucial role in developing and main-
taining rapport and trust – both with those who chose
to enrol in the DAR-901 trial and this qualitative study
and those who declined enrolment in either or both but
who might also still receive their routine clinical care at
this medical institution.
The present study examined which of these complex
motivations predominated among foreign-born HIV-
negative and HIV-infected adults asked to participate in
a Phase 1 vaccine clinical trial. Speaking with such
individuals is not equivalent to speaking with potential
subjects in countries where TB is endemic and a new
vaccine is most likely to be deployed, but our findings
do point to social dynamics that may occur in such con-
texts. Finally, we hope this work informs the relatively
under-studied arena of the lived experiences of foreign-
born individuals who choose to participate in medical
research in the US.
Methods
Phase I TB vaccine study subject recruitment and enrolment
Information about the clinical trial and participant
recruitment was publicised through a variety of commu-
nity events, social networks, and physician-scientist out-
reach to eligible patients, particularly in the case of the
HIV-infected cohort. This generated an initial group of
individuals who approached the study coordinator with
the intent to possibly participate. The study coordinator
would then meet individually for an hour with prospect-
ive participants to explain the trial and review informed
consent materials that described risks and benefits of the
study. This also included a detailed discussion about
what participation in the trial would involve: namely, ten
clinical visits over ten months and six blood draws per
patient, with those who enrolled in the study offered
$600 as remuneration for time and travel. After an initial
screening process to determine eligibility and the in-
depth consent process, 78 subjects agreed to be screened
for the trial and 59 individuals were found to be eligible
and were enrolled in the trial.
Qualitative study of potential subject motivations for
participation
To explore potential research subject motivations to
volunteer – or not – in a Phase I TB vaccine trial, we
conducted 18 in-depth, semi-structured ethnographic
interviews with enrolled and declined study subjects
among three foreign-born cohorts participating in the
DAR-901 study.3 We categorized participants into three
groups:
(1) declined, HIV-negative
(2) enrolled, HIV-negative
(3) enrolled, HIV-infected
By ‘declined,’ we mean subjects who qualified to
participate in the DAR-901 clinical trial and were
approached by study staff with an intention to recruit,
but who declined to participate. We also attempted to
interview HIV-infected subjects who declined to partici-
pate in the trial (a logical fourth cohort), but of the 6
such individuals we contacted, none agreed to partici-
pate in the qualitative study either. This is both a limita-
tion of the research and a notable result in itself.4
To protect confidentiality and facilitate informed
decision-making, we were not put in contact with poten-
tial study participants unless they expressed an affirma-
tive interest in the qualitative study after being appraised
of its nature and goals by the DAR-901 study coordin-
ator, with whom they were in contact throughout the
DAR-901 clinical trial process. Interviews with enrolled
individuals were scheduled concurrently with study visits
in the DAR-901 trial, to minimize the impact of the
qualitative research on participants’ time. Interviews
took place in private locations without the presence of
DAR-901 study staff. Interviews with individuals who
declined to take part in the study took place off-site, at
locations of the individual’s choosing at a time that was
convenient for them.
After establishing basic rapport with potential inter-
viewees, discussing the goal of this qualitative study, and
giving them time to ask questions, we elicited oral
consent to the interview and the audio recording of that
interview. The interview script revolved around open-
ended prompts focused on subjects’ understandings of
tuberculosis as well as ‘clinical research’ in general and
the DAR-901 trial specifically, including follow up ques-
tions about the feasibility of a 3-dose vaccine series. We
asked participants to describe in their own words the
process of being recruited to the trial, their motivations
to volunteer or not, and the nature of that decision-
making process. Interviews allowed for reflections on
the differences in health care and medical systems be-
tween participants’ home countries and the US. In
speaking with study staff, we aimed to gather their per-
spectives on designing and executing this study. The
semi-structured interviews each took about one hour
and were all conducted in English. Interviewees were
given a $50 gift card as compensation for their time.5
As a way of gaining further contextual understanding
of the trial, including processes of recruitment, we also
interviewed five study investigators, including the PIs
and a study coordinator. Study staff expressed interest in
this qualitative study because they had been on the
frontlines of subject recruitment and management of
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enrolled subjects, both of which were intensive. For
example, for the 59 subjects enrolled in the trial, the
study coordinator placed 1416 phone calls and facilitated
nearly 600 patient visits over 10 months.
Upon completion of interviews, we generated tran-
scripts and, along with additional observational field
notes and debriefs between researchers, coded these for
qualitative themes. We have summarized the results
from each cohort based on the open and focused coding
of the interview transcripts.
Results
Table 1 summarizes basic demographics of individuals
who participated in this qualitative study.
To volunteer or not to volunteer?
Participants came from diverse geographic, cultural, and
socioeconomic backgrounds. Education levels varied
significantly, ranging from those with advanced degrees
to those who had received little (less than 3 years) to no
formal primary education in their home country. The
annual tuberculosis incidence rates in countries of origin
varied from very low (Canada 5/100,000; Australia 6/
100,000) to very high (DR Congo 325/100,000; Nigeria
(322/100,000) [53]. Study participants included highly
educated people often employed at the parent academic
institution or hospital, or students in the process of
completing undergraduate or professional degrees; or
people from regions of the world characterized by
political-economic instability who have come to northern
New England as refugees or economic migrants. The
majority of individuals in the HIV-infected cohort had
lived through significant experiences of uncertainty and
trauma, in the context of structural inequality and/or
overt political violence.
In the DAR-901 trial, nearly every encounter between
participants and study staff was cross-cultural in that all
study staff were US citizens who self-identified as white/
Caucasian whereas most foreign-born study subjects in
all cohorts identified as non-white. In the context of our
qualitative study, the first and second authors were
Caucasian US citizens, while the third was a foreign-
born individual who recently became naturalized as a
US citizen.
Our interviews revealed multiple dynamics of volun-
teerism and drivers of medical decision-making in rela-
tion to clinical research; and a variety of understandings
of tuberculosis in general and of the DAR-901 vaccine in
particular.
Enrolled subjects
Study subject motivations to participate in the DAR-901
Phase 1 study centred around a generalized sense of
altruism, often expressed as a desire to ‘help others,’
coupled with a sense that this trial was ‘special.’ Trust in
study staff, a desire to combat TB-related stigma, and fi-
nancial incentives were also motivating factors. Enrolled
subjects were motivated to participate in the DAR-901
trial because of the significance of DAR-901 itself, and
the vaccine’s potential positive impact on global health.
All enrolled participants stressed that they felt they had
a specific contribution to make to this trial, given its
location and inclusion criteria. One HIV-negative subject
said there was ‘no reason not to participate. This [is]
going to help people.’ One subject experienced an
adverse skin reaction to the vaccine, but said she had no
ill will towards the trial investigators because her ‘data
point’ was ‘only going to help the study…I already had
one scar [from BCG], and so I have another one.’
Another participant in the HIV-negative cohort said, ‘If
they were recruiting just any student, I wouldn’t have
been as compelled to do it just because I would have
been, like, I’m sure lots of people are doing it. But there
aren’t that many international students here.’ A third
HIV-negative enrolled subject said her father offered to
pay her not to do the study, presumably for fear of
potential risks, but ‘I felt through doing this study, I was
contributing to something significant…If you have that
opportunity, you should take it, as long as it is not going
to inversely impact your health and well-being…This is
eventually going to help people and keep them healthy.’
Others echoed this sense that any risks of participation
in the study were outweighed by the potential to
contribute to ‘overcoming a huge disease burden’ as
another enrolled HIV-negative participant put it. One
HIV-infected individual said, ‘The danger is minimal, the
benefit is tremendous. People everywhere have been
kind to me, so…’.
Motivations for participation also involved conceptions
of perceived direct and indirect benefit. Not all individ-
uals we interviewed had direct experience with TB, but
some did, either by having tested positive for TB expos-
ure themselves, through relatives who had suffered from
the disease, or in recognition of high mortality and
Table 1 Gender, Age, and Country of Origin of Interviewees
Cohort Gender Average Age Country of Origin
Declined, HIV-negative F:2 M:4 23.7 South Korea [2], Ghana [2], China, Pakistan
Enrolled, HIV-negative F:3 M:3 32 India [3], China, Lebanon, Nigeria
Enrolled, HIV-infected F:3 M:3 47.8 Liberia [2], Cuba, Canada, DR Congo, Australia
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morbidity from TB in their home communities. These
individuals cited experience with TB as a motivation for
participation in the DAR-901 trial. As one HIV-infected
individual described, ‘When I was in Liberia and Ivory
Coast, people died of TB. My daughter had TB…Three
years ago, TB came to her.’ In some cases, enrolled sub-
jects were motivated to participate because of perceived
reduced risk of TB that exposure to the DAR-901 vac-
cine could offer – even though the trial was placebo-
controlled, blinded and experimental. One HIV-negative
subject, who had tested positive for TB exposure but
decided not to take the recommended prophylactic anti-
biotic regimen, thought that his participation ‘may just
help keep me healthy. You never know.’ Another in the
HIV-infected cohort cited the growing number of new
immigrants to the US (although he was also an immi-
grant) and the possibility for increased TB exposure. ‘I
know it won’t hurt me and it might offer some protec-
tion as the world continues to change.’
Only individuals in the HIV-infected cohort cited a
desire to reduce TB-related stigma as a motivation for
volunteerism. While discussion of HIV serostatus was
not universal – and actively avoided by some subjects –
all but one HIV-infected study subject mentioned TB-
related stigma as a reason to participate in the DAR-901
vaccine trial. One individual spoke about seeing how
people with TB were treated in his country of origin:
‘People who were ‘shunned, ostracized…or treated like
human garbage’ due to their TB status. Another individ-
ual described how her nephew died of TB and her family
was affected by the stigma. She explained that despite
the knowledge that TB is curable, ‘there can be whole
areas of the hospital that are under quarantine but also
deeply marked by stigma related to TB. People assume
that if you have TB, you also have HIV.’ Even though
her nephew was HIV-negative, ‘nobody would come visit
him in the hospital.’ These individuals saw the possibility
of an effective TB vaccine as a way to put an end to
stigma as well as improve health in their countries of
origin.
Enrolled interviewees described trust of study staff
who also served as clinicians where they receive care as
a motivation to participate. As one person put it, ‘I’m
close to them. [Without a personal connection] I don’t
think I would have considered it.’ Some enrolled study
subjects expressed sympathy for the challenges of study
recruitment as a factor motivating participation. ‘From
doing clinical research myself…I know it’s sometimes
really hard to recruit subjects and so that can really slow
your progress.’ Those in the HIV-infected cohort were
directly motivated to participate by the trust they had in
their providers. As one individual put it, ‘I hope it works.
I hope it makes it so I don’t get TB. I hope Dr. X makes
more vaccines. He should make one for HIV.’
A stated sense of altruism and a sense that this trial
was both ‘special’ and ‘important’ did not necessarily cor-
relate with a willingness to tell others about their partici-
pation. In fact, the majority of interviewees said they
discussed their enrolment in this study with either no-
body or only a few people. Not all study participants told
their spouse or parents that they participated. Others
actively kept their enrolment from loved ones. As one
HIV-negative participant said, ‘It would just be too much
explain and they’d be worried or tell me not to do it
because it’s not good for me.’ In another case, a HIV-
infected enrolled individual said she would not share in-
formation about her participation with others, although
she had enrolled in the trial.
Friends [possibly others who live in the region and
had been approached about participating in this trial]
called me to ask if I was going to participate. I said
no, I am not participating….In Africa, we keep secrets.
We don’t want anyone but God or the data people for
this study to know our secrets.
This individual went on to describe the logics of
‘sending sickness’ [54] and how this pervaded her
decision-making processes. Sharing information could
render her vulnerable. Interestingly, this individual expli-
citly stated that her main interlocutor in the decision
about participation was God. ‘God owns me, owns my
life,’ she said – a comment that not only dovetailed with
a stated Christian ethic of ‘helping others’ as motivation
for participation but also toward much more wide-
ranging aspects of her lived experience: her survival
through civil war, rape, HIV infection, and immigration
to the US.
Study subjects did not always receive support for par-
ticipation from loved ones if they did decide to tell them.
Only one interviewee mentioned his decision to enrol to
everyone in his family. ‘My mom was the only one who
was a bit concerned because, obviously, there is risk
associated with everything. Her not being a biologist, I
explained it [the idea of a booster vaccine] to her but
there was still a sceptical side to her.’ One HIV-negative
participant, a healthcare provider himself whose parents
are both physicians in his country of birth, said that
when he mentioned the possibility of his participation,
they tried to dissuade him. ‘They were just fearful that
there would be some side effects,’ he explained. In the
end, he decided to enrol in the study but declined to tell
his parents, actively denying participation when they
asked. In these two cases and others, a desire to be altru-
istic led to deception within a social circle.
Money was a motivator for some participants, since they
would earn approximately $600 for participation in the
DAR-901 trial. Remuneration was especially appealing to
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younger subjects, such as undergraduate students, and
those who were working low-paying jobs or on govern-
ment assistance. Conversely, payment was a dis-incentive
to others who interpreted the remuneration rate as reflect-
ive of risk. Some felt that remuneration was suspiciously
high. ‘The more [the trial] pay[s], the more [the trial is]
hiding something,’ said one enrolled individual. Others felt
the trial was not paying enough given the amount of time
that the trial demanded. One enrolled individual said, ‘I do
research also… so I understand the need to recruit people
and I do understand there’s not enough money to be flash-
ing around to get people, but … if you are going to try to
entice people and ask them to do a series of tests…the
money incentive could have been higher.’
Declined subjects
In interviews with individuals who declined participation
in the DAR-901 trial, they said they were simply not in-
terested enough in the study to volunteer or that the ‘in-
convenience’ and time commitment required of the trial
was prohibitive. However, time was not the only factor
discouraging study participation. Most individuals who
declined participation said they were averse to the idea,
as one person put it, of ‘adding anything unnecessary to
one’s body.’ This was true even for people who had a
medical and/or clinical research background. Some
people who declined participation said they no longer
see TB as a deadly disease or they might not have direct
exposure to TB disease. Interestingly, those who voiced
this reason did not give it as their own rationale for de-
clining participation; rather they cited it as a rationale
advanced by individuals who influenced their decision.
Interviewees who declined to participate also cited scep-
ticism about clinical research in general. Many noted
concerns that the trial’s remuneration structure signalled
a hidden risk in the vaccine itself.
Some speculated about how TB was transmitted, in-
cluding discussing the possibility that risk of TB expos-
ure could somehow be heightened by their participation
in the trial; two individuals expressed a lack of trust in
study staff. However, this was not a dominant sentiment.
Indeed, one interviewee whose work schedule eventually
precluded study enrolment said that trust for the
clinician-scientists made him still feel ‘committed’ to the
trial, even though he could not participate directly.
None of the interviewees who declined participation
expressed an overt sense of fear as their reason for de-
clining participation, but several speculated that others
might have declined participation because of fear about
the vaccine or its associated risks. Some individuals
voiced general suspicion about clinical research, even if
this was not directed at this trial. ‘In general, people
have a lot respect for physicians, but sometimes that re-
spect is abused…Even in the US, there have been many
medical trials on minorities that will give someone pause
before joining something like this.’ The subjects empha-
sized how important trust was in even attracting them
to get more information about the trial. Without the
personal connections that many subjects had to DAR-
901 researchers, they would not have even considered
participating in the first place.
One individual who declined to participate did so be-
cause her family forbade her out of concern for vaccine
risk. ‘[I declined] because my husband won’t allow it be-
cause he thinks it was dangerous.’ When asked if she
would have volunteered if her husband had not inter-
vened, she enthusiastically said she would ‘because it
helps make the vaccine better, and TB has a lot of
impact on the health of developing countries like China.
If this booster works, this will do good to not only the
US but many countries in the world. But my husband is
very stubborn.’
Tuberculosis, vaccines, and DAR-901
Understandings of tuberculosis varied widely among
those we interviewed. Highly educated individuals –
both those who enrolled and those who declined – dis-
cussed disease aetiology and pathology in technical bio-
medical terms. Interviewees with undergraduate degree
or lower education could provide a general description
of the disease, with one exception. Among subjects with-
out a medical background, a basic understanding of the
disease was often tied to exposure to social media and
other public health campaigns in their countries of ori-
gin. As one declined individual described, ‘We grew up
learning about the Seven Killer Diseases, which are the
diseases you get vaccinated for as a child. And TB is one
of them.’ As another declined subject described, ‘TB is
commonly referred to in movies and shows, so everyone
has a general idea that the disease affected the lungs and
results in coughing up blood.’ In some instances, this
basic familiarity with TB and with the BCG vaccine
translated into easier conversations with those in a social
or medical decision-making circle about the idea of a
‘booster vaccine.’ Others found it more difficult to de-
scribe the potential benefits of this new vaccine, and
knowledge of TB was more limited to a discussion of its
symptoms (e.g. ‘coughing blood’) and associated social
stigmas (e.g. as a sign of ‘being HIV positive’).
In response to general questions about the purpose of
the DAR-901 trial recruitment criteria, all enrolled and
declined individuals articulated understanding that the
trial required testing this new vaccine on people who
had received BCG vaccines in their countries of origin.
Among the HIV-infected cohort, understanding of the
trial’s goals and the science behind the administration of
a vaccine booster varied widely. However, the founda-
tional understanding that this was a vaccine which was
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being developed to help prevent TB was clear to all par-
ticipants, as was the understanding that a new vaccine
would ‘boost’ or enhance the immunity provided by the
‘old vaccine’ [BCG]. All but one subject articulated an
understanding that DAR-901 was similar to BCG, but
‘hopefully better.’ The majority of interviewees were sur-
prised to learn that BCG did not provide lifelong protec-
tion; prior to their participation in the DAR-901 trial,
many had assumed that no further vaccine would be
needed. ‘I feel it was very interesting… that the TB
vaccine [BCG], after a certain amount of years, was no
longer effective. But we never knew. Our knowledge
[was] that it [BCG] is [for a] lifetime, and we never really
worried.’
Individuals expressed a range of opinions about vac-
cines in general. Many interviewees voiced a belief in the
role that vaccines play in disease prevention. Fears about
vaccines did not come up as a reason to decline partici-
pation in the DAR-901 trial, but underlying medical un-
derstandings behind such decisions varied. For example,
as one declined subject said, ‘Vaccines are not as danger-
ous as drugs because they’re helping. You prevent some-
thing. But drugs are poison to help you get rid of some
condition.’ This individual indicated that they were more
inclined to participate in a vaccine trial than they would
have been to participate in a drug trial. Another individ-
ual in the HIV-infected cohort viewed vaccines posi-
tively: ‘I used to run to a vaccine camp when it came [to
our village],’ she said, referring specifically to early child-
hood vaccination efforts in her country of origin. ‘I used
to try to get everyone to come. People would carry
babies, and I used to think that everyone should come
to do the vaccines to be healthy.’
And yet, this same individual later said that her reac-
tion was not necessarily the norm in her community,
citing dynamics of fear and mistrust of biomedical
authority. She used the 2014 Ebola outbreak in West
Africa, and a possible Ebola vaccine, as a cautionary tale.
When discussing the possibility of administering DAR-
901 in her country of origin, she said, ‘Before you give,
you have to explain very well. Most people will be afraid.
People thought vaccines brought Ebola.’ In a similar
vein, another interviewee acknowledged the association
of militarized medicine with histories of colonial vio-
lence. He emphasized the ‘public relations’ work that
would need to be done in ‘some countries’ to ‘combat
the idea of “What are these white faces doing to us?”…
You would need good education and marketing cam-
paigns. You would have to say, “This vaccine is going to
save lives.” Because anti-vaccine sentiment is something
that is real on the social and political side of things.’
In contrast, most interviewees reasoned that for DAR-
901 to be tested on people like them in the US, it must
have been rigorously tested before (some specifying
animal trials) and deemed safe. Many expressed a gen-
eral confidence in ‘the government’ and ‘agencies that
approve clinical research,’ even though most interviewees
(except those involved in clinical research themselves)
could not name which federal agency would need to give
its approval for a new vaccine to be put into widespread
clinical use.
Such comments also often led to discussions of the
contrast between the US health system compared to the
system they knew in their country of origin. As one
participant expressed, war and political instability in her
central African country has meant that ‘there is no real
health care.’ This individual went on to describe how
‘you have to sometimes pawn your belongings, like a TV,
to pay for the care that you need to receive in the health
care system.’ She continued, ‘If you have a surgery for
your appendix, you have to bring your own blood serum.
Outside of the hospital setting, many people just try to
treat themselves, relying on home remedies or trad-
itional medicines.’
Many subjects mentioned schools and churches as
ideal sites for administration, and felt that this should be
something offered through public health care. In con-
trast, some noted dynamics of distrust, either saying that
they would not trust the quality of the vaccine if it came
from the state instead of an international nongovern-
mental organization. A declined HIV-negative subject
noted, ‘In China…now, the hospital has become a much
more economically independent unit. You have to man-
age and make [money]. Each hospital…has to make
money and one way is through their pharmacies.’
Although most participants felt that general awareness
of TB was high in their countries of origin, they also said
that many probably were still under the impression that
they were protected from TB if they received BCG,
unless they were HIV-infected.
Discussion: Research and lived experience, consent and
culture
As our qualitatively coded data revealed, altruism, scepti-
cism, personal commitments, self-interest and monetary
incentives all contribute to the decision-making of poten-
tial research study subjects. We found this was true in the
foreign-born BCG immunized patients in both the HIV-
negative and HIV-infected cohorts we interviewed, and
that the specifics of the clinical research question modified
these dynamics. We found there was an interplay between
narratives of sacrifice and those of giving back, between
altruism and scepticism, as well as tensions between
individual and collective sensibilities about volunteering
for medical research. These dynamics were inflected by
cultural sensibilities on the one hand, such as through
ethno-physiological conceptions of risk [55], and experi-
ences of structural inequality on the other, such as the lack
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of access to health care in a country of origin or the lived
impacts war. We heed Farmer’s call ([56]: p. 47–48) not to
conflate cultural difference with structural violence,
including when it comes to making sense of people’s
decisions about whether or not to volunteer for clinical
research.
While many individuals were willing to participate in
medical research, they were less willing to talk about
their participation in clinical research with others. Altru-
istic expressions were coupled with a desire for privacy,
concerns about what friends and family would think, or
responses to others’ fears about participation. This find-
ing reflects the ways that individual and social drivers
can both compel and hinder volunteerism and compli-
cates narratives that would equate such actions with a
sense of recognized or visible social action. Altruism,
while common, was also complicated by the ways some
individuals tied participation in the trial to possibilities
for direct personal benefit, either in the form of possible
protection from TB or financial gain. Volunteerism in
this context was also shaped by many enrolled partici-
pants’ perceptions of the US health care system as well
as respect and trust for the physician-scientists involved
in this trial, including trusted intermediaries who used
social and clinical networks to make initial introductions
between potential participants and study staff.
Despite a detailed informed consent form and discus-
sion between study subjects and study staff, there was
significant variation among those we interviewed about
what a vaccine is and what it can and can’t do. These
findings raise interesting questions about how informed
consent can be influenced by cultural difference, educa-
tion, socioeconomic position, and other aspects of lived
experience, as others have also discussed [48, 57–62].
Several interviewees questioned whether some popula-
tions would ever be able to give fully informed consent,
either because of sustained challenges of language and
culture or because of broader differences in worldview
and distinct social dynamics that shape the consent
process. One declined individual cited the sense that
‘Asian societies have a collectivist mentality and this
desire to benefit the greater good would take precedent
over individual harm.’ However, this same individual
(from South Korea) went on to say that ‘with
modernization, Korea now has idea of western ethics so
there is now a similar definition of informed consent for
both countries.’ Collective decision-making practices
clearly influenced many potential study subjects, either
by discouraging participation or influencing disclosure
of a decision to participate.
Interviewees were aware of the potential blurred
boundaries between clinical research and clinical care, as
they relate to the political-economy of medical research,
research ethics, and the ‘outsourcing’ of clinical trials to
less ‘developed’ countries. These topics came up in all
but two interviews. Beyond comparisons of clinical trials
which study vaccine versus drugs advanced by a corpor-
ation, interviewees spoke about how financial incentives,
either to individuals or institutions in under-resourced
settings, could influence research. Some interviewees de-
scribed a sense of imbalance in how clinical research
seemed to be conducted in their countries of origin.
They expressed desires for these efforts to be more
‘ethical’ or more ‘mutually beneficial’ to the communities
in which the research is conducted. One declined subject
said,
In most cases, when the funding dries up or the
project winds up, that [is] it. The Europeans and the
Americans just walk out and are fine. Essentially,
you’ve utilized [our] bodies, you’ve gained knowledge,
personal, professional, and academic advancement.
And, in return, [you’ve] hired a few people and built a
few buildings, but [you] haven’t really given [us]
anything.
Another interviewee pointed out that even if a subject
population is truly informed and fully consenting, their
agency could still be limited or threatened if was not
protected by the judiciary in country in which research
is being done. ‘If your patient population is well-
educated, they know their rights. And if you have a good
law enforcement system, then they can actually exercise
their rights, as opposed to the patient population not
knowing their rights and not necessarily understanding
the risks,’ One enrolled subject described. ‘They don’t
have the privilege to go sue someone. In which case, I
can see [medical researchers] going in with good inten-
tions but I can still the patient population getting
exploited.’
Subjects in our study recognized that, in cases where
people feel that clinical research is their only option for
clinical care, true informed consent is impossible. One
study staff member shared that the head of an institu-
tional review board in a country in which he had
conducted research once questioned him about ‘why
Americans wasted time splitting hairs’ over the details of
ethics review. As long as a trial was providing care for
patients, this official argued, what did ethics review
matter?
Study staff involved in this trial and in the previous
SRL-172 trial in Tanzania noted that while FDA regula-
tions are very stringent in the US, WHO regulations are
less consistently enforced in Tanzania. They observed
that the subject pool in Tanzania was more vulnerable
than those in the US because they recognized that
clinical research was connected to a source of primary
care. One staff member noted, ‘While most subjects in
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America are looking to put gravy on their potatoes, most
subjects in Tanzania are looking for the potatoes
themselves.’ On this topic, one declined subject said,
‘Some people [are] waiting to die, so why not get free
treatment?’ Such comments not only speak to this re-
search versus care dynamic, but also point to differences
between a vaccine trial of this type and a drug trial, even
if such distinctions may at times be lost on study sub-
jects. We summarize our coded findings in terms of the
key motivations and concerns of enrolees in the tubercu-
losis vaccine trial in Table 2.
Conclusion
Using in-depth semi-structured interviews of declined
and enrolled study subjects in the DAR-901 trial, we
identified major themes influencing foreign-born
individuals’ decisions about whether or not to enrol in a
phase I TB vaccine clinical trial which took place in the
United States. Individuals who chose to enrol in the
DAR-901 trial linked a generalized sense of altruism
with a very specific understanding of what this vaccine
could accomplish. Study enrolees believed they were
contributing meaningfully to a valid and beneficial scien-
tific endeavour, run by people who were both qualified
and cared about the participants and about improving
health outcomes generally, and reducing TB mortality,
morbidity, and stigma specifically. For those who
declined enrolment, generalized scepticism about the
motivations of physician-scientists, the ethical challenges
of clinical research, and perceptions of personal risk
were articulated alongside more mundane concerns
about timing and effort required to participate. Financial
incentives were a motivating factor for some and a locus
of scepticism for others. Personal relationships between
study staff and research subjects were crucial to recruit-
ment and successful completion of the trial.
Insights from this study can help inform outreach and
recruitment, informed consent, and education efforts in
ongoing and future clinical trials involving foreign-born
individuals. This study provides useful cross-cultural
feedback at a critical moment in TB vaccine develop-
ment. Our findings highlight the perceived value and
need for a TB vaccine; they also identify opportunities
for education about the limits of BCG. We also found
Table 2 Key motivations and concerns of enrolees in the tuberculosis vaccine trial
Coded theme Dynamic Response
Knowledge (direct/indirect) of tuberculosis Many subjects were motivated to participate
due to awareness of the tuberculosis
epidemic and the role of tuberculosis
vaccines in disease prevention
Educate potential subjects about public
health problem addressed by study & how
intervention aims to help people
Altruism Subjects participated in study to aid
development of tuberculosis vaccine
Mention potential for study participation to
help at-risk communities
Personal relationships Study subjects with connections to clinicians
involved in study or trusted intermediaries
who recommend participation were
motivated to participate
Non-coercive invitation to participate in
study by known clinicians where possible
Personal gain Some subjects expect to benefit clinically
from participation
Transparency about potential study benefits,
if any. It is important for subjects to
understand that their decision to participate
in study (or not) should have no impact on
quality of clinical care
Privacy Many subjects limited release of information
about study participation & its indications
Protect subject privacy in accordance with
their preferences
Collective decision-making The opinions of respected peers, including
family members, influenced many
approached individuals to participate or not
During consent conversation, ask potential
subjects if they would like study staff to
discuss study with respected peers as well
(unless privacy of decision already
mentioned)
Remuneration Financial incentives to participate in the
study were viewed positively by some
subjects & with suspicion by others
Select a non-coercive incentive to
participate in collaboration with
representation from communities from
which recruiting subjects
Convenience Time required of subjects in trial can
dis-incentivise participation
Be parsimonious with subject time
investments; align financial incentives to
them
Risk aversion Some subjects declined out of fear the
vaccine could harm them
Educate subjects about risks/benefits of
study intervention & measures taken to
observe & mitigate them during conduct of
trial
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that TB stigma, collective decision-making, and tailored
health communications were highly influential to potential
TB vaccine trial subjects. Results from these qualitative in-
terviews reiterate the need and value of developing relation-
ships with trusted community leaders (including clinician-
scientists) as part of the research effort. These data also
raise productive questions about the possibilities and limits
of non-coercive incentives for participation in clinical re-
search, and suggest the enduring importance of continued
conversation about the process of conducting ethical,
culturally-sensitive, and relationship-influenced science.
Endnotes
1Aeras is a non-profit foundation charged with
advancing the development of TB vaccines.
2DAR-901, is an inactivated polyantigenic whole cell
mycobacterial vaccine. An earlier form of DAR-901,
called SRL 172, was used in a seven-year Phase III in
Tanzania sponsored by the U.S. National Institutes of
Health and involving adults with HIV infection who
received BCG at birth. In that trial, receipt of SRL 172
was associated with significantly lower risk of
microbiologically-proven tuberculosis. This trial remains
the only trial in which a new tuberculosis vaccine has
shown efficacy in humans. Dartmouth and the global TB
vaccine research foundation Aeras collaborated to de-
velop an improved and scalable method for manufactur-
ing the vaccine, now designated DAR-901.
3Dartmouth College Committee for the Protection of
Human Subjects (CPHS) approved this study (CPHS
#28941).
4We had several informal phone conversations with de-
clined HIV-infected individuals, who initially expressed
interest in participating in the qualitative study. However,
these individuals eventually declined, citing work schedule
difficulties in one instance and some mistrust of clinical
research (being ‘experimented on’) in another.
5This level of compensation was determined in
relation to what enrolled subjects were being paid for
their participation in the clinical trial itself.
Abbreviations
BCG : bacilli Calmette-Guerin (vaccine); HIV : human immunodeficiency virus;
TB : tuberculosis; US : United States; WHO : World Health Organization
Acknowledgements
The authors thank all participants in this qualitative study, as well as the
study staff, particularly Brenda Haynes, as well as David Leib and L’uaie
Kailani for their support and encouragement for this work.
Funding
The parent trial was funded by Aeras. This interview analysis of potential
subject motivation to participate in a phase I TB vaccine trial was funded by
SYNERGY, The Dartmouth Clinical and Translational Science Institute, a
program of the National Institutes of Health (NIH) Clinical and Translational
Science Award (CTSA) program, “Phase I trial of DAR-901 in foreign-born HIV
positive subjects: safety and volunteerism.”
Availability of data and materials
The datasets generated and/or analysed during the current study are not
publicly available due to issues of participant privacy, but are available from
the corresponding author on reasonable request.
Authors’ contributions
SRC conducted interviews with the enrolled, HIV-infected population and was
the primary contributor to data analysis and article writing. TL contributed to
the concept and design of the study and was a major contributor in writing
the manuscript. AD conducted interviews with the declined, HIV-negative
population, enrolled, HIV-negative population, and study staff. AD and CFR
contributed writing the article, both through the engagement of study data
with wider literature and editing the manuscript through to submission stage.
All authors read and approved of the submitted manuscript.
Ethics approval and consent to participate
The Dartmouth Committee for the Protection of Human Subjects, which is
the name for Dartmouth’s Institutional Review Board/Ethics Committee,
approved this study (CPHS #28941). In the ethics review process, we received
permission for a waiver of written consent, and instead the researchers
obtained verbal consent from all of the participants. We documented this
verbal consent on a password-protected information sheet and de-identified
transcript of the interview. The study also provided all participants with an
information sheet detailing the purpose of the study and how their
information would be shared and used.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Anthropology, Dartmouth College, 6047 Silsby Hall, Hanover,
NH 03755, USA. 2Geisel School of Medicine, Dartmouth College, Hanover,
USA. 3Dartmouth College, Hanover, USA.
Received: 8 August 2017 Accepted: 12 April 2018
References
1. WHO End TB Strategy [Internet]. World Health Organization; 2015 [cited
2017 Jun 19]. Available from: http://www.who.int/tb/post2015_strategy/en/
2. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis
elimination. Annu Rev Public Health. 2013;34:271–86.
3. Lahey T, von Reyn CF. Mycobacterium bovis BCG and New Vaccines against
Tuberculosis. In: Tuberculosis and Nontuberculous Mycobacterial Infections,
Sixth Edition [Internet]. American Society of Microbiology; 2011 [cited 2017
Jun 8]. p. 162–181. Available from: http://www.asmscience.org/content/
book/10.1128/9781555817138.ch10
4. Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A,
et al. Impact and cost-effectiveness of new tuberculosis vaccines in
low-and middle-income countries. Proc Natl Acad Sci. 2014;111(43):
15520–1552.
5. The Global Pipeline of TB Vaccine Candidates [Internet]. Aeras. [cited 2017
Jun 8]. Available from: http://www.aeras.org/pages/portfolio-approach
6. Kaufmann SH, Weiner 3rd J, Maertzdorf J. Accelerating tuberculosis
vaccine trials with diagnostic and prognostic biomarkers. Expert Rev
Vaccines [Internet]. 2017 [cited 2017 Jul 19];(just-accepted). Available
from: http://www.tandfonline.com/doi/abs/10.1080/14760584.2017.
1341316
7. von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, et al.
Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected
adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS.
2010;24(5):675–85.
8. von Reyn CF, Lahey T, Arbeit RD, Landry B, Kailani L, Adams LV, et al. Safety
and immunogenicity of an inactivated whole cell tuberculosis vaccine
booster in adults primed with BCG: a randomized, controlled trial of
DAR-901. PLoS One. 2017;12(5):e0175215.
Craig et al. BMC Public Health  (2018) 18:535 Page 10 of 12
9. Verheggen FWSM, Nieman F, Jonkers R. Determinants of patient
participation in clinical studies requiring informed consent: why patients
enter a clinical trial. Patient Educ Couns. 1998;35(2):111–25.
10. Locock LSL. Personal benefit, or benefiting others? Deciding whether to
take part in clinical trials. Clinical Trials London, England. 2011;8(1):85–93.
11. Wright JRWT, Schiff S, Dubois S, Crooks D, Haines PT, et al. Why cancer
patients enter randomized clinical trials: exploring the factors that influence
their decision. J Clin Oncol. 2004;22(21):4312–8.
12. Dainesi SM, Goldbaum M. Reasons behind the participation in biomedical
research: a brief review. Rev Bras Epidemiol. 2014;17(4):842–51.
13. Nappo SIG, Sanchez ZM. Motives for participating in a clinical research trial:
a pilot study in Brazil. BMC Public Health. 2013;13(19)
14. Mtunthama NMR, French N, Molyneux ME, Zijlstra EE, Gordon SB. Malawians
permit research bronchoscopy due to perceived need for healthcare.
J Med Ethics. 2008;34(4):303–7.
15. Zammar GMH, Shah J, Phadtare A, Cofiel L, Pietrobon R. So different, yet so
similar: meta-analysis and policy modeling of willingness to participate in
clinical trials among Brazilians and Indians. PLoS One. 2010;5(12):e14368.
https://doi.org/10.1371/journal.pone.0014368.
16. Tarimo EAMTA, Kohi TW, Bakari M, Mhalu F, Kulane A. Reasons for declining
to enroll in a phase O and II HIV vaccine trails after randomization among
eligible volunteers in Dar es Slaam, Tanzania. PLoS One. 2011;6(2):e14619.
https://doi.org/10.1371/journal.pone.0014619.
17. Marshall PA, Koenig BA, Grifhorst P, Van Ewijk M. Ethical issues in immigrant
health care and clinical research. In: Handbook of immigrant health
[Internet]. Springer; 1998 [cited 2017 Jun 8]. p. 203–226. Available from:
http://link.springer.com/10.1007/978-1-4899-1936-6_11
18. Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and
the management of latent tuberculosis infection in immigrants to the
United States. N Engl J Med. 2002;347(23):1850–9.
19. Cain KP, Benoit SR, Winston CA, Mac Kenzie WR. Tuberculosis among
foreign-born persons in the United States. JAMA. 2008;300(4):405–12.
20. Petryna A. When experiments travel: clinical trials and the global search for
human subjects: Princeton University Press; 2009.
21. Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials.
Nat Rev Drug Discov. 2008;7(1):13–4.
22. Truong THWJ, Cook EF, Joffe S. Altruism among participants in cancer
clinical trials. Clin Trials. 2011;8(5):616–23.
23. McCann SKCMK, Entwistle VA. Reasons for participating in randomized
controlled trials: conditional altruism and considerations for self. Trials. 2010;11
24. Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S, Erlichman C. Patients'
willingness to enter clinical trials: measuring the association with perceived
benefit and preference for decision participation. Soc Sci Med.
1991;32(1):35–42.
25. Schutta KM, Burnett CB. Factors that influence a patient’s decision to
participate in a phase I cancer clinical trial. In: Oncology Nursing Forum
[Internet]. 2000 [cited 2017 Jun 8]. p. 1435–1438. Available from: http://
europepmc.org/abstract/med/11058975
26. Jain SL. Malignant: how cancer becomes us: Univ of California Press; 2013.
27. Lowther K, Harding R, Ahmed A, Gikaara N, Ali Z, Kariuki H, et al.
Conducting experimental research in marginalised populations: clinical and
methodological implications from a mixed-methods randomised controlled
trial in Kenya. AIDS Care. 2016;28(Suppl 1):60–3.
28. Hall S, Goddard C, Speck PW, Martin P, Higginson IJ. “It makes you feel that
somebody is out there caring”: a qualitative study of intervention and
control participants’ perceptions of the benefits of taking part in an
evaluation of dignity therapy for people with advanced Cancer. J Pain
Symptom Manag. 2013;45(4):712–25.
29. Sachs B. The exceptional ethics of the investigator-subject relationship.
J Medicine and Philosophy. 2010;35(1):64–80.
30. Sahay S, Kumar M, Srikrishnan AK, Ramanathan V, Mehendale S.
Experiences in recruiting volunteers through community-based
initiatives in Phase-1 vaccine trials in India. Hum Vaccines Immunother.
2014;10(2):485–91.
31. Bigorra J, Banos JE. Weight of financial reward in the decision by medical
students and experienced healthy volunteers to participate in clinical trials.
Eur J Clin Pharmacol. 1990;38(5):443–6.
32. Stunkel LGC. More than money: a review of the literature examining healthy
volunteer motivations. Contemporary Clinical Trials. 2011;32(3):342–52.
33. Russell ML, Moralejo DG, Burgess ED. Paying research subjects: participants
perspectives. J Med Ethics. 2000;26(2):126–30.
34. Reed E, Fisher CB, Blakenship KM, West BS, Koshnood K. Why female sex
workers participate in HIV research: the illusion of voluntariness. AIDS Care.
2017;29(7):914–8.
35. Tishler CL, Bartholomae S. The recruitment of normal healthy volunteers: a
review of the literature on the use of financial incentives. J Clin Pharmacol.
2002;42(4):365–75.
36. Vere DW. Payments to healthy volunteers-ethical problems. Br J Clin
Pharmacol. 1991;32(2):141–2.
37. Donald R, Hoover BCEAM. Attitudes of adolescents/young adult women
toward human papilloma virus vaccination and clinical trials. Health Care for
Women International. 2000;21(5):375–91.
38. Erves JC, Mayo-Gamble TL, Hull PC, Duke L, Miller ST. Adolescent
participation in HPV vaccine clinical trials: are parents willing? J Community
Health. 2017;42(5):894–901.
39. Brintnall-Karabelas JSS, Cadman ME, Squires C, Whorton K, Pao M. Improving
recruitment in clinical trials: why eligible participants decline. J Empir Res
Hum Res Ethics. 2011;6(1):69–74.
40. Corbie-Smith G, Thomas SB, George DMMS. Distrust, race, and research.
Arch Intern Med. 2002;162(21):2458–63.
41. Igwe E, Woodburn J, Davolos J, et al. Patient perceptions and willingness to
participate in clinical trials. Gynecol Oncol. 2016;142(3):520–4.
42. Lock M. Nguyen V-K. An Anthropology of Biomedicine: John Wiley & Sons;
2010.
43. Wong YN. Shared benefits of clinical research should come with shared
responsibility. 2013.
44. Masiye FKN, Hyder A, Ndebele P, Mfutso-Bengo J. Why mothers choose to
enroll their children in malaria clinical studies and the involvement of
relatives in decision making: evidence from Malawi. Malawi Med J.
2008;20(2):50–6.
45. Annas GJ. Globalized clinical trials and informed consent. N Engl J Med.
2009;360(20):2050–3.
46. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA,
Califf RM, et al. Ethical and scientific implications of the globalization
of clinical research [Internet]. Mass Medical Soc; 2009 [cited 2017
Jun 8]. Available from: http://www.nejm.org/doi/full/10.1056/
NEJMsb0803929
47. Shapiro HT, Meslin EM. Ethical issues in the design and conduct of clinical
trials in developing countries [Internet]. Mass Medical Soc; 2001 [cited 2017
Jul 19]. Available from: http://www.nejm.org/doi/pdf/10.1056/
NEJM200107123450212.
48. Adams V, Miller S, Craig S, Le PV, Varner M. Others. Informed consent in
cross-cultural perspective: clinical research in the Tibetan autonomous
region, PRC. Cult Med Psychiatry. 2007;31(4):445–72.
49. Regmi PR, Aryal N, Kurmi O, Pant PR, Teijlingen E, Wasti SP. Informed
Consent in Health Research: Challenges and Barriers in Low-and Middle-
Income Countries with Specific Reference to Nepal. Dev World Bioeth
[Internet]. 2016 [cited 2017 Jul 19]; Available from: http://onlinelibrary.wiley.
com/doi/10.1111/dewb.12123/full.
50. Dawson L, Kass NE. Views of US researchers about informed consent in
international collaborative research. Soc Sci Med. 2005;61(6):1211–22.
51. Sankar P. Communication and miscommunication in informed consent to
research. Med Anthropol Q. 2004;18(4):429–46.
52. Steinke EE. Research ethics, informed consent, and participant recruitment.
Clin Nurse Spec. 2004;18(2):88–97.
53. WHO Global Tuberculosis Report [Internet]. World Health Organization; 2016
[cited 2017 Jun 5]. Available from: http://www.who.int/tb/publications/
global_report/en/
54. Farmer P. Sending sickness: sorcery, politics, and changing concepts of AIDS
in rural Haiti. Med Anthropol Q. 1990;4(1):6–27.
55. Nichter M. Global health: why cultural perceptions, social representations,
and biopolitics matter: University of Arizona Press; 2008.
56. Farmer P. Pathologies of power: health, human rights, and the new war on
the poor. Vol. 4. In: Univ of California press; 2004.
57. Barata PC, Gucciardi E, Ahmad F, Stewart DE. Cross-cultural perspectives on
research participation and informed consent. Soc Sci Med. 2006;62(2):479–90.
58. Shafiq N, Malhotra S. Ethics in clinical research: need for assessing
comprehension of informed consent form? Contemp Clin Trials. 2011;32(2):169–72.
59. Vallely A, Lees S, Shagi C, Kasindi S, Soteli S, Kavit N, et al. How informed is
consent in vulnerable populations? Experience using a continuous consent
process during the MDP301 vaginal microbicide trial in Mwanza, Tanzania.
BMC Med Ethics. 2010;11(1):10.
Craig et al. BMC Public Health  (2018) 18:535 Page 11 of 12
60. Molyneux CS, Peshu N, Marsh K. Trust and informed consent: insights from
community members on the Kenyan coast. Soc Sci Med. 2005;61(7):1463–73.
61. Fitzgerald DW, Marotte C, Verdier RI, Johnson WD, Pape JW. Comprehension
during informed consent in a less-developed country. Lancet. 2002;
360(9342):1301–2.
62. Kripalani S, Bengtzen R, Henderson LE, Jacobson TA. Clinical research in
low-literacy populations: using teach-back to assess comprehension of
informed consent and privacy information. IRB Ethics Hum Res.
2008;30(2):13–9.
Craig et al. BMC Public Health  (2018) 18:535 Page 12 of 12
